💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, reasonably priced.
Alembic Pharma is scored on the pharma / healthcare framework. It keeps a slim 9.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.17× reported profit. Free cash flow is worth about 1.5% of its market value.
Over the last 3 years revenue compounded at 9%/yr and profit at 25%/yr. Book value has grown 9%/yr. Return on equity is a healthy 14.2%. In the latest quarter profit fell 14% versus the prior quarter.
At 28× earnings, the stock sits at the 27th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~11%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 22.61 | — | — |
| P/B | 3.19 | 4.11 | better |
| EV/EBITDA | 13.28 | 19.15 | better |
| ROE | 14.2 | — | — |
| ROCE | 13.66 | 6.87 | better |
| ROA | 8.81 | — | — |
| Quick Ratio | 0.78 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 9% CAGR — growing but slowly.
Profit is growing faster than revenue (25% vs 9%) — margin expansion is at work.
Operating margin has expanded from 6% to 9% — the business is keeping more of each rupee earned.
ROE at 12% — modest; the capital isn't working hard.
25% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 16% sequentially — momentum is building.
Profit fell 14% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 69.9% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.